Focused On-demand Library for Vitamin D-binding protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P02774

UPID:

VTDB_HUMAN

Alternative names:

Gc protein-derived macrophage activating factor; Gc-globulin; Group-specific component; Vitamin D-binding protein-macrophage activating factor

Alternative UPACC:

P02774; B4DPP2; D6RAK8; Q16309; Q16310; Q53F31; Q6GTG1

Background:

The Vitamin D-binding protein, also known as Gc-globulin, plays a crucial role in vitamin D transport and storage. It is also involved in scavenging extracellular G-actin, enhancing chemotactic activity of C5 alpha for neutrophils, and macrophage activation. Its alternative names include Gc protein-derived macrophage activating factor and Group-specific component.

Therapeutic significance:

Understanding the role of Vitamin D-binding protein could open doors to potential therapeutic strategies. Its involvement in immune response and vitamin D metabolism highlights its potential as a target for therapeutic intervention.